Acrux and US-based pharmaceutical giant Eli Lilly and Co agreed to end their licensing deal for Axiron, a testosterone replacement therapy for men. Axiron was the first testosterone replacement product that could be applied like a roll-on deodorant on the armpit of a patient. Acrux said generic treatments for testosterone deficiency were creating commercial uncertainty, and the testosterone market was declining.
The costs of a clinical trial required by the US Food and Drug Administration to determine whether an increased risk of heart attack or stroke exists among users of testosterone were also uncertain, the company said. Acrux is also appealing a US court decision that held that patents for the Axiron formulation were invalid.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
